4Frishman WH, Huberfeld S, Okin S,et al. Serotonin and serotonin antagonism in cardiovascular and non-cardiovasculardisease[J]. J Clin Pharmacol,1995,35(6):541.
5Malik A, Shapiro JM, Yanics J, et al. A simplified method for producing rapidventricular hypertrophy[J]. Cardiovasc Res,1976,8(7):801.
6Tomanek RJ, Buffeers CA, Zimanmu MB. Initiation of cardiac hypertrophy in responeto thyroxine is not limited by age[J]. Am J Physiol, 1993,264(4 pt2):H1041.
7Miller FP,Cox RH, Snodgrass WR,et al. Comparative effects of PCPA,PCA,PCMA on ratbrain norepinephrine, serotonin and 5-hydroxyindole-3-acetic acid[J]. Biochem Pharmacol,1970, 19(3):435.
8Linden A, Desmecht D, Amory H, et al.Cardiovascular response to intravenousadministration of 5-hydroxytryptamine after type-2 receptor blockade, by metrenperone, inhealthy calves[J]. Vet J, 1999, 157(1):31.
9Cobo C, Alcocer L, Chez A, et al. Effects of ketanserin on left ventricularhypertrophy in hypertensive patients[J]. Cardiol Drug Ther, 1990,4(S1):73.
10Vyssoulis GP, Karpanou EA, Pitsavos CE, et al. Comparison of ketanserin andceliprolol on regression of left ventricular hypertrophy in older hypertensivesubjects[J]. Cardiol Drug Ther, 1992,6(4):419.
